Democrats' drug pricing reforms may not be so bad for pharma, analysts say

The legislation has drawn the ire of drugmakers and industry groups alike, who contend the price negotiations are more akin to price controls. Another common refrain centers around the law’s potential to stifle biopharma innovation.

But the reality may not be so bad for the industry, with the true influence of the law on biopharma companies being marginal, analysts from Bank of America and UBS wrote in notes seen by Seeking Alpha.